Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415031 · ClinicalTrials.gov registry record · Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
A Phase 2 study, sponsored by Mirati Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT07415031 is a Phase 2 study that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 170 participants.
The verdict
NCT07415031, a Phase 2 study, is actively recruiting participants, sponsored by Mirati Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG Adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2028-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07415031
The ClinicalTrials.gov registry entry for NCT07415031 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07415031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07415031 about?
NCT07415031 is a clinical study titled "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies". This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorect...
What is the current status of trial NCT07415031?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2026-05-06. Estimated completion is 2028-02-16.
What interventions are being tested in trial NCT07415031?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT07415031?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.